A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)

Inclusion Criteria:

• Have type 2 diabetes

• Have HbA1c ≥7.0% (≥53 mmol/mol) to ≤9.5% (≤80 mmol/mol)

• Are currently on a stable dose of dulaglutide weekly (0.75 mg or 1.5 mg) for atleast 6 months prior to screening.

• No treatment with oral antihyperglycemic medication (OAM), or on a stable dose of upto 3 OAMs, which may include metformin, sodium glucose cotransporter-2 inhibitors (SGLT-2i), and/or sulfonylurea, for at least 3 months before screening.

• Have had stable body weight (±5%) during the 90 days preceding screening

• Have BMI ≥25 kilogram/square meter (kg/m²)

Exclusion Criteria:

• Have type 1 diabetes

• Have a history of chronic or acute pancreatitis

• Have a history of

• proliferative diabetic retinopathy, or

• diabetic maculopathy, or

• nonproliferative diabetic retinopathy that requires acute treatment.

• Have any of these cardiovascular (CV) conditions within 60 days prior to screening:

• acute myocardial infarction,

• cerebrovascular accident (stroke), or

• hospitalization due to congestive heart failure (CHF).

• Have New York Heart Assocation (NYHA) Functional Classification Class IV CHF

• Have family or personal history of medullary thyroid carcinoma (MTC) or multipleendocrine neoplasia syndrome type 2 (MEN2).

• Have within 90 days prior to screening received treatment with medications intendedto promote weight loss. This includes prescribed, over-the-counter, or alternativeremedies

• Have an estimated glomerular filtration rate (eGFR) <30 mL/minute/1.73 m2 (or lowerthan the country-specific threshold for discontinuing metformin therapy per locallabel)

• Have been treated with insulin prior to screening

• Exception: use of insulin for gestational diabetes or short-term use (<14 days)for acute conditions such as acute illness, hospitalization, or electivesurgery.

• Have a history of reduction of dose of dulaglutide, due to intolerability, withoutsuccessful reescalation